Insulin manufacturers reduce prices globally within 12 months

If the U.S. caps insulin prices at $35/month, global manufacturers (e.g., Novo Nordisk, Sanofi) will voluntarily reduce prices in other markets to align with U.S. standards. This will trigger similar regulatory pressure in Europe and Canada.

Implied probability (Yes)

60%